Targeting Treatable Traits in COPD to Prevent Hospitalisations (TERRACOTTA)

  • George, Johnson (Primary Chief Investigator (PCI))
  • Abramson, Michael (Chief Investigator (CI))
  • Holland, Anne (Chief Investigator (CI))
  • Bell, Simon (Chief Investigator (CI))
  • Paul, Eldho (Chief Investigator (CI))
  • McDonald, Vanessa (Chief Investigator (CI))
  • Bonevski, Billie (Chief Investigator (CI))
  • McDonald, Christine (Chief Investigator (CI))
  • Zwar, Nick (Chief Investigator (CI))
  • Dharmage, Shyamali Chandrika (Chief Investigator (CI))
  • Mahal, Ajay (Chief Investigator (CI))
  • Hancock, Kerry (Chief Investigator (CI))

Project: Research

Project Details

Project Description

A pragmatic, single-blind, cluster randomised controlled trial will be conducted nationally in GP clinics (n=40). Community dwelling adults with a history of moderate-severe COPD will be identified within each clinic (n = 10) by trained practice nurses. Control clinic subjects (n=200) will receive a booklet on ‘lung health’. The intervention includes a multidimensional assessment by a practice nurse to characterise TTs in patients with COPD that will lead to a personalised medicine approach targeting pulmonary, extrapulmonary and behavioural traits. In the intervention group (n=200), trained practice nurses will coordinate: a personalised COPD action plan, home-based pulmonary rehabilitation, home medicines review, smoking cessation support, and tailored mobile phone-based risk reduction support. Changes in HRQoL at 6 months is the primary efficacy end point. Respiratory acute hospital visits per participant at 6 and 12 months will be assessed.
Short titleTargeting treatable traits in copd
AcronymTERRACOTTA
StatusActive
Effective start/end date15/12/201/06/25

Keywords

  • COPD
  • Treatable Traits
  • health-related quality of life
  • hospitalisation